Science-backed, internationally used overdose prevention sites are being underutilized and often ignored in America. But that’s not the only way to save lives not being used. We’re also failing to adequately deploy lifesaving medication — buprenorphine — particularly among our young people.

Buprenorphine is an evidence-based treatment that has been available for more than three decades. It can displace full opioids such as morphine or methadone without their risks of overdose, misuse, or dependency. Despite the availability of buprenorphine, overdose fatalities among 14 to 18 year olds have nearly tripled in the last 3 years.

Few medications pediatricians can prescribe are life-saving. Buprenorphine is. Restricting access to life-saving medications is a failure to intervene early and effectively. One-third of adults in treatment for opioid addiction started using opioids before age 18 and two-thirds before age 25.

Why aren’t more youth being given this treatment? Three reasons: misdiagnosis, a preference for other, less effective treatments, and rules prohibiting them from getting this treatment confidentially.

Advertise with us

The problem starts with misdiagnosis. Providers who care for youth often miss incidences of opioid use disorder because it’s considered an “adult problem.” In a Canadian study from 2021, 88% of youth had interacted with healthcare in an acute setting in the year leading up to their diagnosis of opioid use disorder (OUD). That suggests medical personnel missed opportunities for diagnosis and treatment.

But even when youth struggling with opioid use receive the proper diagnosis, they too rarely receive effective treatment. A 2017 study revealed that just one in four youths between the ages of 13 and 24 diagnosed with OUD receive medications for opioid use disorder (MOUD), such as buprenorphine or naltrexone.

Instead, they more commonly receive abstinence-based residential treatment or outpatient psychosocial therapy. Both have high rates of dropout and return to use.

Researchers have found that with medication, adolescents remain in treatment for between 17 weeks and a year compared to counseling alone. Those receiving counseling remain in treatment an average of 10 weeks.

More importantly, even if buprenorphine is available, young people are unlikely to access it without the ability to consent to it in confidence. Though forty-four of fifty states have provisions that allow minors to consent for substance use treatment without parental consent, most of this treatment is the ineffective abstinence-based residential treatment or outpatient psychosocial therapy.

Advertise with us

This is because federal legislation requires that youth with OUD have two documented unsuccessful attempts at short-term detoxification or drug-free treatment within a 12-month period to even qualify for MOUD. A parent, legal guardian, or responsible adult must also consent in writing for a young person to receive MOUD.

Confidential consent is important for young people. In a survey of high school students, 25% reported that they would not seek health care for issues they wanted to keep private if there was a possibility that their confidentiality could be compromised.

Adolescents need confidential access to buprenorphine. And there are models for young people to confidentially consent. The state of Massachusetts has developed a consent form for a person aged 12 to 17 to obtain MOUD with verification of substance use disorder (SUD) by two physicians. The consent form could be adapted nationally to allow for more states to allow minors access to buprenorphine confidentially. The federal policy could also allow for a similar exception to its current requirement of written parental consent for MOUD.

Finally, federal initiatives could work to strengthen pediatric medical training. Currently, there is only one fellowship program nationwide for pediatric addiction, and pediatric trainees often do not have addiction medicine as part of their curriculum.

Providing grant funding for virtual platforms that offer training in buprenorphine induction and maintenance, integrating addiction medicine into pediatric training programs, and creating initiatives for outpatient pediatricians to prescribe buprenorphine are some strategies to increase appropriate diagnosis and treatment of OUD.

Advertise with us

Nationally, we are at a critical juncture about how we choose to tackle preventable deaths from opioids. Stigma, incarceration, and abstinence-based treatments have failed. Providers deserve the ability to prevent harm through confidential care and young people deserve confidential care that works.

Megana Dwarakanath is a fellow in adolescent medicine at UPMC Children's Hospital.